New drug CMAB017 enters human trials for Hard-to-Treat cancers
NCT ID NCT06933069
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new drug called CMAB017 in 55 people with advanced solid tumors (like head and neck cancer or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for any signs that the drug shrinks tumors, but this is not the primary focus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CMAB017 (a drug given by intravenous infusion)
What this could lead to
If this trial shows CMAB017 is safe and has anti-tumor activity, it could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial with only 55 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••